Idrish Ali

Dr. Idrish Ali is a Senior Research Fellow at Monash University's Faculty of Medicine, Department of Neuroscience, where he leads research on the neurobiology of acquired epilepsy using preclinical models with a specialized focus on brain inflammation. He maintains an active external research position at the University of Melbourne since April 2017 and serves as Primary Chief Investigator on multiple national and international research projects funded by NIH, NHMRC, DoD, and industry partners.

His research program centers on developing imaging techniques to measure brain inflammation as biomarkers for predicting epilepsy following brain insults, while simultaneously applying pharmacological and genetic interventions to modify inflammatory pathways. Key methodological contributions include pioneering MRI harmonization protocols for multicenter preclinical traumatic brain injury studies through the EpiBioS4Rx consortium, establishing standardized seizure detection pipelines, and developing novel in vivo biomarkers for GABAergic function assessment in chronic epilepsy models.

Dr. Ali's publication record demonstrates consistent output with 46 research outputs since 2008, accelerating to 11 publications in 2023 and 12 in 2024. His work shows strong emphasis on translational biomarker development, with 60% of recent publications focusing on preclinical-to-clinical translation of inflammation-based epilepsy biomarkers. The research exhibits methodological diversity spanning neuroimaging, molecular biology, electrophysiology, and behavioral phenotyping across multiple model systems including rats, mice, and zebrafish.

His scientific recognition includes:

• ECR Travel Grant (2022)
• $25,000 GIN Hub funding for 'Role of granulocyte-colony-stimulating factor signalling in epilepsy' (2022)
• M2 Polarization of microglia award targeting temporal lobe epilepsy (2017)

As an active PhD supervisor accepting students through Monash's Supervisor Connect platform, Dr. Ali leads multiple concurrent projects including the NIH-funded 'Translational platform for epilepsy therapy and biomarker discovery' (2022-2026), NHMRC Equipment Grant for Lateral Fluid Percussion Injury device, and DoD-funded 'Measuring inflammation in brain and blood for predicting risk of post-traumatic epilepsy'. His collaborative network spans 25+ institutions across 5 countries, with particularly strong ties to the O'Brien research group at Monash where his laboratory is embedded.

Dr. Ali's research infrastructure includes specialized capabilities in multimodal neuroimaging harmonization, in vivo biomarker development, and inflammatory pathway modulation, operating within the O'Brien Group's neuroscience research ecosystem at Monash University.